logo
Plus   Neg
Share
Email

Novartis To Buy Cadent Therapeutics For Up To $770 Mln - Quick Facts

Novartis (NVS) announced Thursday that it has agreed to buy all of the outstanding capital stock of Cadent Therapeutics. Cadent and Novartis anticipate the transaction will close during the first quarter of 2021.

Upon the closing of deal, Cadent Therapeutics said it will receive $210 million upfront and up to $560 million in milestone payments, for a potential total of $770 million.

Novartis specified that this acquisition adds two new clinical stage programs to the Novartis neuroscience portfolio, one for schizophrenia and the other for movement disorders.

The acquisition also includes MIJ821, a clinical stage molecule that Novartis licensed exclusively from Cadent in 2015 for treatment-resistant depression.

Cadent Therapeutics is a privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mediterranean Food Inc is recalling its "Alqosh Sesame Oil" citing the potential to be contaminated with Salmonella, the U.S. Food and Drug Administration said. The affected Alqosh Sesame Oil "Tahin" comes in a 2Lb, clear plastic jar marked with lot # 16082020 on the side of the jar and with a Production date of 08/16/2020 stamped on the side. Twitter has filed a lawsuit against Texas Attorney General Ken Paxton, seeking to halt his ongoing investigation into the company's content moderation practices. Paxton, a Republican and supporter of former president Donald Trump, on January 13 had sent a civil investigative demand or CID to Twitter after its decision to permanently suspend Trump from the social media platform... The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test.
Follow RTT